Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12935144 | 0.85 | PDE10A (0.32) | PDE10A | |
| SCHEMBL275977 | 0.84 | PDE10A (0.48) | PDE10APDK2TDP1LMNAPDK4 | |
| SCHEMBL77166 | 0.77 | LMNA (0.30) | LMNA | |
| SCHEMBL10376639 | 0.77 | LMNA (0.50) | PDK2TDP1LMNAPDK4 | |
| SCHEMBL801870 | 0.77 | ALDH1A1 (0.39) | PDE10A | |
| SCHEMBL439985 | 0.73 | PDE10A (0.39) | PDE10A | |
| SCHEMBL24538435 | 0.72 | PDE10A (0.34) | PDE10APDK2TDP1 | |
| SCHEMBL9830230 | 0.72 | KMT2A (0.37) | TDP1 | |
| SCHEMBL22655948 | 0.72 | TDP1 (0.31) | TDP1 | |
| SCHEMBL10813311 | 0.72 | PDE10A (0.34) | PDE10APDK2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3870577-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV HEALTHCARE UK NO 5 LTD (GB) | 2025-03-19 | — | — | EP | disclosed |
| US-20240174662-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | CILAG AG (CH) | 2024-05-30 | — | — | US | disclosed |
| EP-4284802-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | Janssen Biotech, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| US-11678574-B2 | Compound and organic light emitting diode comprising same | LG CHEM, LTD. (KR) | 2023-06-13 | — | — | US | disclosed |
| US-11678574-B2 | Compound and organic light emitting diode comprising same | LG CHEM, LTD. (KR) | 2023-06-13 | — | — | US | disclosed |
| US-20230109662-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | VIIV Healthcare UK (No.5) Limited (GB) | 2023-04-06 | — | — | US | disclosed |
| WO-2023014611-A1 | PYRIMIDINE COMPOUNDS AND USE THEREOF | YEH, TENG-KUANG (US) | 2023-02-09 | — | — | WO | disclosed |
| US-11541055-B2 | Inhibitors of human immunodeficiency virus replication | VIIV Healthcare UK (No.5) Limited (GB) | 2023-01-03 | — | — | US | disclosed |
| US-20220389028-A1 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY | 2022-12-08 | — | — | US | disclosed |
| WO-2022165530-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | JANSSEN BIOTECH, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| US-7696204-B2 | Pharmaceutical compounds | LUDWIG INSTITUTE FOR CANCER RESEARCH (CH) | 2010-04-13 | — | — | US | disclosed |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-18 | — | — | US | disclosed |
| US-7507733-B2 | 11b-HSD1 inhibitors for the treatment of diabetes | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20090042884-A1 | Pharmaceutical Compounds | F.HOFFMANN-LA ROCHE AG (CH) | 2009-02-12 | — | — | US | disclosed |
| EP-1763517-A2 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-21 | — | — | EP | disclosed |
| WO-2006000371-A2 | PYRIMIDINE DERIVATIVES AS 11BETA-HSD1 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-01-05 | — | — | WO | disclosed |
| US-20050288308-A1 | 11B-HSD1 inhibitors for the treatment of diabetes | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-29 | — | — | US | disclosed |
| US-4608383-A | Cardioactive pyrazole and imidazole aryloxypropanolamines | BOEHRINGER MANNHEIM GMBH (DE) | 1986-08-26 | — | — | US | disclosed |
| US-4438128-A | ADRENERGIC BLOCKERS | BOEHRINGER MANNHEIM GMBH (DE) | 1984-03-20 | — | — | US | disclosed |
| EP-0042593-A1 | Aryloxy-propanol amines, process for their preparation and medicines containing these compounds | Roche Diagnostics GmbH (DE) | 1981-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288308-A1 | 11B-HSD1 inhibitors for the treatment of diabetes | HSD11B1, HSD17B1, HSD3B1 | PDE10A 465/4885PDK2 207/4885TDP1 1475/4885 |
| US-11541055-B2 | Inhibitors of human immunodeficiency virus replication | EIF2AK2, POLR2E, POLR2H | PDE10A 3414/4885PDK2 2977/4885TDP1 1193/4885 |
| US-20090042884-A1 | Pharmaceutical Compounds | PIK3CA, JAK1, PIK3R1 | PDE10A 653/4885PDK2 75/4885TDP1 186/4885 |
| US-11678574-B2 | Compound and organic light emitting diode comprising same | CYP1A1, ARL1, ALDH1A1 | PDE10A 4725/4885PDK2 2667/4885TDP1 2694/4885 |
| US-20230109662-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | EIF2AK2, POLR2E, POLR2H | PDE10A 3414/4885PDK2 2977/4885TDP1 1193/4885 |
| US-20090156601-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF CANCER | NR3C1, NR4A3, NR4A1 | PDE10A 3517/4885PDK2 2822/4885TDP1 1346/4885 |
| US-20240174662-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | SIK2, SIK1, SGK2 | PDE10A 1926/4885PDK2 343/4885TDP1 2246/4885 |
| US-20220389028-A1 | BAX INHIBITORS AND USES THEREOF | BAX, TMBIM6, BCL2 | PDE10A 3700/4885PDK2 846/4885TDP1 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.